JP2023500654A - １型肝腎症候群及び低い平均動脈圧を有する患者を治療する方法 - Google Patents

１型肝腎症候群及び低い平均動脈圧を有する患者を治療する方法 Download PDF

Info

Publication number
JP2023500654A
JP2023500654A JP2022525323A JP2022525323A JP2023500654A JP 2023500654 A JP2023500654 A JP 2023500654A JP 2022525323 A JP2022525323 A JP 2022525323A JP 2022525323 A JP2022525323 A JP 2022525323A JP 2023500654 A JP2023500654 A JP 2023500654A
Authority
JP
Japan
Prior art keywords
terlipressin
patient
days
administration
hrs
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022525323A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023500654A5 (https=
Inventor
クーラム ジャミル，
スティーブン クリス パッパス，
ピーター テューバー，
Original Assignee
マリンクロット ホスピタル プロダクツ アイピー アンリミテッド カンパニー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by マリンクロット ホスピタル プロダクツ アイピー アンリミテッド カンパニー filed Critical マリンクロット ホスピタル プロダクツ アイピー アンリミテッド カンパニー
Publication of JP2023500654A publication Critical patent/JP2023500654A/ja
Publication of JP2023500654A5 publication Critical patent/JP2023500654A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/095—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
JP2022525323A 2019-10-30 2020-10-29 １型肝腎症候群及び低い平均動脈圧を有する患者を治療する方法 Pending JP2023500654A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962928152P 2019-10-30 2019-10-30
US62/928,152 2019-10-30
PCT/IB2020/060185 WO2021084483A1 (en) 2019-10-30 2020-10-29 Method of treating patients with hepatorenal syndrome type 1 and low mean arterial pressure

Publications (2)

Publication Number Publication Date
JP2023500654A true JP2023500654A (ja) 2023-01-10
JP2023500654A5 JP2023500654A5 (https=) 2023-11-07

Family

ID=73060034

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022525323A Pending JP2023500654A (ja) 2019-10-30 2020-10-29 １型肝腎症候群及び低い平均動脈圧を有する患者を治療する方法

Country Status (10)

Country Link
US (1) US20210128676A1 (https=)
EP (1) EP4051310A1 (https=)
JP (1) JP2023500654A (https=)
KR (1) KR20220092868A (https=)
CN (1) CN114980914A (https=)
AU (1) AU2020373408A1 (https=)
BR (1) BR112022006329A2 (https=)
CA (1) CA3159575A1 (https=)
MX (1) MX2022004157A (https=)
WO (1) WO2021084483A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240019089A (ko) * 2021-06-07 2024-02-14 말린크로트 파마슈티칼스 아일랜드 리미티드 간신장 증후군 1형 환자의 치료 방법

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015203036A1 (en) * 2010-07-14 2015-07-02 Cumberland Emerging Technologies, Inc Methods of Treating Hepatorenal Syndrom and Hepatic Encephalopathy with Thromboxane-A2 Receptor Antagonists
US10335452B2 (en) * 2014-10-24 2019-07-02 Mallinckrodt Hospital Products IP Limited Method of treating patients with hepatorenal syndrome type 1

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
"Mallinckrodt presents terlipressin clinical data at the Liver Meeting(R) 2018", NEWS RELEASE, MALLINCKRODT PHARMACEUTICALS [ONLINE](RETRIEVED ON 2024 NOV 22), JPN6024048312, 9 November 2018 (2018-11-09), ISSN: 0005599305 *
"NCT00089570", CLINICALTRIALS.GOV [ONLINE](RETRIEVED ON 2024 NOV 22), JPN6024048310, 27 October 2017 (2017-10-27), ISSN: 0005599307 *
"NCT01143246", CLINICALTRIALS.GOV [ONLINE](RETRIEVED ON 2024 NOV 25), vol. Version 28, JPN6024048311, 8 September 2016 (2016-09-08), ISSN: 0005599306 *
ALIMENT PHARMACOL THER., vol. 45, JPN6024048309, 2017, pages 1390 - 1402, ISSN: 0005599308 *
GASTROENTEROLOGY, vol. 134, JPN6024048308, 2008, pages 1360 - 1368, ISSN: 0005599309 *

Also Published As

Publication number Publication date
CA3159575A1 (en) 2021-05-06
EP4051310A1 (en) 2022-09-07
US20210128676A1 (en) 2021-05-06
MX2022004157A (es) 2022-07-19
CN114980914A (zh) 2022-08-30
KR20220092868A (ko) 2022-07-04
AU2020373408A1 (en) 2022-04-21
BR112022006329A2 (pt) 2022-08-16
WO2021084483A1 (en) 2021-05-06

Similar Documents

Publication Publication Date Title
JP7346494B2 (ja) １型肝腎症候群患者の治療方法
JP6962943B2 (ja) 腎不全を処置するための組成物及び方法
US20240374674A1 (en) Method of treating patients with hepatorenal syndrome type 1
CN111920939A (zh) 血管紧张素ii单独或以组合方式用于治疗低血压
US20220143132A1 (en) Method of treating patients with hepatorenal syndrome type 1
US20200237856A1 (en) Method of treating patients with hepatorenal syndrome type 1
JP2023500654A (ja) １型肝腎症候群及び低い平均動脈圧を有する患者を治療する方法
US20250276033A1 (en) Compositions for improving kidney function in patients with hepatorenal syndrome
KR20240019089A (ko) 간신장 증후군 1형 환자의 치료 방법

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231027

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231027

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241128

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250227

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250521